Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Source: 
BioCentury
snippet: 

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab.